抗获得性免疫缺陷综合征复方制剂研究进展

doi:10.19803/j.1672-8629.20240275

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (9): 978-984.
DOI: 10.19803/j.1672-8629.20240275

• 复方与联合用药安全性评价专栏（二） • 上一篇下一篇

抗获得性免疫缺陷综合征复方制剂研究进展

孙思曼^1,2, 江海燕², 范潇予², 李万芳^2,3, 包捷^2,3, 王川^1#, 靳洪涛^2,3,4,*

¹陕西中医药大学药学院,陕西咸阳 712046;
²中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050;
³北京协和建昊医药技术开发有限责任公司,北京 100176;
⁴国家药品监督管理局创新药物安全研究与评价重点实验室,北京 102206

收稿日期:2024-04-28 出版日期:2024-09-15 发布日期:2024-09-14
通讯作者: ^*靳洪涛,男,研究员·博导,药物毒理学。E-mail:jinhongtao@imm.ac.cn。^#为共同通信作者。
作者简介:孙思曼,女,在读硕士,药学。
基金资助:
国家自然科学基金资助项目(82074104); 中国毒理学会临床毒理学转化研究课题(CST2021CT101)

Research progress in anti-AIDS compound preparations

SUN Siman^1,2, JIANG Haiyan², FAN Xiaoyu², LI Wanfang^2,3, BAO Jie^2,3, WANG Chuan^1#, JIN Hongtao^2,3,4,*

¹College of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang Shanxi 712046, China;
²New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
³Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd., Beijing 100176, China;
⁴NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug, Beijing 102206, China

Received:2024-04-28 Online:2024-09-15 Published:2024-09-14

摘要/Abstract

摘要： 目的综述复方制剂在获得性免疫缺陷综合征（AIDS）治疗领域的开发原则及要求,总结抗逆转录病毒疗法（ART）的简化方案,为寻求最佳的药物治疗方案提供参考。方法通过检索国内外相关文献及数据库,对已上市的复方制剂进行整理、分析和归纳。结果目前已上市的抗AIDS复方制剂可以简化ART方案,提高用药依从性,减少药物毒副作用,降低药物负担,提高患者生活质量。结论抗AIDS的复方制剂在治疗方面具有显著优势,但该病的治疗和药物研发仍然存在着重大临床需求,需进一步深入研究。

关键词: 人类免疫缺陷病毒, 获得性免疫缺陷综合征（艾滋病）, 联合用药, 复方制剂, 药物开发

Abstract: Objective To outline the principles and requirements of developing compound preparations against acquired immunodeficiency syndrome (AIDS), and summarize the simplified regimens of antiretroviral therapy (ART) so as to provide references for seeking the best drug therapy regimens. Methods By searching related domestic and foreign literature and databases, the compound preparations against AIDS on the market were sorted out and analyzed. Results The currently marketed compound preparations against AIDS could simplify ART regimens, enhance medication compliance, reduce drug side effects, lower the drug burden, and improve patients' quality of life. Conclusion Compound preparations against AIDS have significant advantages therapeutically, but there are still significant clinical needs for the treatment of and drug development for this disease, which requires more in-depth research.

Key words: human immunodeficiency virus, acquired immune deficiency syndrome (AIDS), combination drug, compound preparation, drug development

中图分类号:

R916
R978

孙思曼, 江海燕, 范潇予, 李万芳, 包捷, 王川, 靳洪涛. 抗获得性免疫缺陷综合征复方制剂研究进展[J]. 中国药物警戒, 2024, 21(9): 978-984.

SUN Siman, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, WANG Chuan, JIN Hongtao. Research progress in anti-AIDS compound preparations[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 978-984.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240275

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/978

参考文献

[1] HE YZ, CHEN XT, CHEN JL, et al.Changes and progress of AIDS antiviral therapy drugs in China[J]. Guangdong Medical Journal(广东医学), 2023, 44(2): 157-160.
[2] OH KS, SEO GH, CHOI HK, et al.Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea[J]. Sci Rep, 2022, 12(1): 2031.
[3] TANG LL, HUANG HP.Impurity control for compound preparation and its impact on product optimization[J]. Modern Chemical Research(当代化工研究), 2023(19): 188-190
[4] CHEN GL, ZHANG L, CHEN P, et al.The status and prospect of research and development of drug combinations[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(19): 2205-2210.
[5] FOKA FET, MUFHANDU HT.Current ARTs, virologic failure, and implications for AIDS management: a systematic review[J]. Viruses, 2023, 15(8): 1732.
[6] CAO XJ, CAO J, QI H, et al.HIV-1 primary drug resistance at home and abroad[J]. Journal of Modern Medicine & Health(现代医药卫生), 2022, 38(24): 4226-4230.
[7] Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center For Disease Control and Prevention. Chinese AIDS diagnosis and treatment guidelines (2024 Edition)[Z]. Chinese Journal of Infectious Diseases(中华传染病杂志), 2024.
[8] FU ZP, KANG DW, LIU XY, et al.New progress of target-based anti-AIDS drugs[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(9): 681-697.
[9] AMBLARD F, PATEL D, MICHAILIDIS E, et al.HIV nucleoside reverse transcriptase inhibitors[J]. Eur J Med Chem, 2022, 240: 114554.
[10] GULICK RM, RIBAUDO HJ, SHIKUMA CM, et al.Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection[J]. N Engl J Med, 2004, 350(18): 1850-1861.
[11] ZHU YJ, MEI PF, XU QQ, et al.Quantitative study of HIV-1 RNA in plasma and HIV-1 DNA in cells of patients treated with highly effective antiviral therapy[J]. Chinese Preventive Medicine(中国预防医学杂志), 2022, 23(3): 167-170.
[12] EDWARDS Z, INGOLD CJ, AZMAT CE.Zidovudine[M]. Treasure Island: StatPearls Publishing LLC, 2024.
[13] MA HL, LI JW, LIU A, et al.Clinical observation of antiviral treatment of HIV based on zidovudine and lamivudine tablets[J]. Chinese Journal of AIDS & STD(中国艾滋病性病), 2016, 22(8): 605-607.
[14] PORTSMOUTH SD, SCOTT CJ.The renaissance of fixed dose combinations: Combivir[J]. Ther Clin Risk Manag, 2007, 3(4): 579-583.
[15] HUANG WY, GUO SY, ZHANG XD.Clinical efficacy, medicinal mechanism and adverse reactions of classical and novel AIDS antiviral drugs[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2022, 17(1): 51-55.
[16] ASTUTI N, MAGGIOLO F.Single-tablet regimens in HIV therapy[J]. Infect Dis Ther, 2014, 3(1): 11-17.
[17] DEEKS ED, PERRY CM.Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla^®): a review of its use in the management of HIV infection[J]. Drugs, 2010, 70(17): 2315-2338.
[18] DEJESUS E, YOUNG B, MORALES-RAMIREZ JO, et al.Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients[J]. J Acquir Immune Defic Syndr, 2009, 51(2): 163-174.
[19] MUCCINI C, CASTAGNA A.A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults[J]. Expert Rev Anti Infect Ther, 2023, 21(11): 1167-1176.
[20] DEEKS ED.Darunavir: a review of its use in the management of HIV-1 infection[J]. Drugs, 2014, 74(1): 99-125.
[21] JIANG TY, LI B, WANG W, et al.Research progress of darunavir in treatment of HIV infection[J]. Chinese Journal of AIDS & STD(中国艾滋病性病), 2020, 26(7): 783-786, 790.
[22] ERON JJ, ORKIN C, GALLANT J, et al.A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients[J]. Aids, 2018, 32(11): 1431-1442.
[23] SCARSI KK, HAVENS JP, PODANY AT, et al.HIV-1 Integrase inhibitors: a comparative review of efficacy and safety[J]. Drugs, 2020, 80(16): 1649-1676.
[24] SCOTT L J.Dolutegravir/Lamivudine single-tablet regimen: a review in HIV-1 infection[J]. Drugs, 2020, 80(1): 61-72.
[25] DE CLERCQ E, ZHANG Z, HUANG J, et al.Biktarvy for the treatment of HIV infection: progress and prospects[J]. Biochem Pharmacol, 2023, 217: 115862.
[26] BAI J, ZHANG C.Application and research progress of Bienpranol in the treatment of acquired immune deficiency syndrome[J]. Clinical Medication Journal(临床药物治疗杂志), 2021, 19(3): 20-25.
[27] CENTO V, PERNO CF.Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety[J]. J Glob Antimicrob Resist, 2020, 20: 228-237.
[28] LLIBRE JM, HUNG CC, BRINSON C, et al.Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies[J]. Lancet, 2018, 391(10123): 839-849.
[29] RHEE SY, KASSAYE SG, BARROW G, et al.HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates[J]. J Int AIDS Soc, 2020, 23(9): e25611.
[30] MOHAMED H, GURROLA T, BERMAN R, et al.Targeting CCR5 as a component of an HIV-1 therapeutic strategy[J]. Front Immunol, 2021, 12: 816515.
[31] NAKATA H, MAEDA K, DAS D, et al.Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s[J]. Sci Rep, 2019, 9(1): 4828.
[32] HEREDIA A, LATINOVIC O, GALLO RC, et al.Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1[J]. Proc Natl Acad Sci USA, 2008, 105(51): 20476-20481.
[33] FAIVRE N, VEROLLET C, DUMAS F.The chemokine receptor CCR5: multi-faceted hook for HIV-1[J]. Retrovirology, 2024, 21(1): 2.
[34] GULICK RM, SU Z, FLEXNER C, et al.Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211[J]. J Infect Dis, 2007, 196(2): 304-312.
[35] AIAMKITSUMRIT B, DAMPIER W, MARTIN-GARCIA J, et al.Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences[J]. PLoS One, 2014, 9(9): e107389.
[36] KUFEL WD.Antibody-based strategies in HIV therapy[J]. Int J Antimicrob Agents, 2020, 56(6): 106186.
[37] JACOBSON JM, LALEZARI JP, THOMPSON MA, et al.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults[J]. Antimicrob Agents Chemother, 2010, 54(10): 4137-4142.
[38] ELLWANGER JH, KAMINSKI VL, CHIES JA.What we say and what we mean when we say redundancy and robustness of the chemokine system - how CCR5 challenges these concepts[J]. Immunol Cell Biol, 2020, 98(1): 22-27.
[39] SUN L.Design, synthesis and bioactivity evaluation of novel HIV-1 capsid protein inhibitors and RNase H inhibitors[D]. Jinan: Shandong University, 2021.
[40] SEGAL-MAURER S, DEJESUS E, STELLBRINK HJ, et al.Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection[J]. N Engl J Med, 2022, 386(19): 1793-1803.
[41] GUPTA SK, BERHE M, CROFOOT G, et al.Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial[J]. Lancet HIV, 2023, 10(1): e15-e23.
[42] PAIK J.Lenacapavir: first approval[J]. Drugs, 2022, 82(14): 1499-1504.

抗获得性免疫缺陷综合征复方制剂研究进展

Research progress in anti-AIDS compound preparations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	江海燕, 周甜雨, 范潇予, 李万芳, 包捷, 靳洪涛. 抗肿瘤复方药物研发现状与挑战[J]. 中国药物警戒, 2024, 21(9): 961-966.
[2]	郭姝姝, 江海燕, 范潇予, 李万芳, 包捷, 马恩龙, 靳洪涛. 基于组分合理性分析高血压复方药物[J]. 中国药物警戒, 2024, 21(9): 973-977.
[3]	申雪, 江海燕, 范潇予, 李万芳, 包捷, 何博赛, 靳洪涛. 联合用药治疗肝纤维化的研究概况与展望[J]. 中国药物警戒, 2024, 21(9): 985-990.
[4]	李金洋. 基于美国FAERS数据库的拉米夫定肾脏及泌尿系统不良事件信号挖掘[J]. 中国药物警戒, 2024, 21(10): 1154-1158.
[5]	严亦舒, 赵岩, 卢天公, 孙震晓. 大黄素-8-O-β-D-葡萄糖苷联合紫杉醇抑制人乳腺癌细胞活力及侵袭转移的研究[J]. 中国药物警戒, 2023, 20(7): 728-734.
[6]	王淑伟, 殷进军, 王冰, 宋彩萍, 杨福俊. 阿昔替尼片联合特瑞普利单抗治疗晚期肾癌致视网膜中央动脉阻塞1例分析[J]. 中国药物警戒, 2023, 20(7): 825-828.
[7]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[8]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.
[9]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[10]	唐炯, 刘颖. 依非韦伦致男性乳房发育1例分析[J]. 中国药物警戒, 2023, 20(11): 1306-1308.
[11]	沈倩, 张蕾. 地佐辛注射液致人类免疫缺陷病毒感染患者成瘾1例分析[J]. 中国药物警戒, 2023, 20(10): 1181-1183.
[12]	孙静, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 崔晓兰. 疏风解毒胶囊联合左氧氟沙星治疗多重耐药铜绿假单胞菌感染性小鼠肺炎的作用研究[J]. 中国药物警戒, 2023, 20(1): 52-56.
[13]	苏鑫鑫, 赵晓晓, 谢雁鸣. 榄香烯乳注射液治疗肝癌患者的真实世界联合用药分析[J]. 中国药物警戒, 2022, 19(9): 929-934.
[14]	黄艳丽, 谢雁鸣, 王连心, 孙粼希, 刘峘, 庄鋆妮. 真实世界老年患者使用刺五加注射液的临床分析[J]. 中国药物警戒, 2022, 19(9): 935-939.
[15]	杜莹, 王志飞, 谢雁鸣, 王连心, 李利寻, 刘志帅. 喜炎平注射液治疗手足口病人群的联合用药方案复杂网络分析[J]. 中国药物警戒, 2022, 19(8): 839-844.